International Journal of Pharmaceutical and Biological Science Archive最新文献

{"title":"ANALYTICAL METHODS FOR ESTIMATION OF MYCOPHENOLIC ACID IN BULK AND IN PHARMACEUTICAL DOSAGE FORM: A REVIEW","authors":"A. U. Manjare, R. Kale","doi":"10.32553/IJPBA.V7I3.127","DOIUrl":"https://doi.org/10.32553/IJPBA.V7I3.127","url":null,"abstract":"Mycophenolic acid is an anti-metabolite immunosuppressant. It also inhibits the enzyme inosine monophosphate dehydrogenase; essential for purine synthesis. High performance liquid chromatography (HPLC) and the UV are an essential analytical tools in assessing drug product. HPLC methods should be able to isolate, detect, and enumerate the various drugs and drug associated degradants that can form on storage, or manufacturing. It should also detect and enumerate any drugs and drug-related impurities that may be introduced during synthesis. Validation is the process of establishing the performance characteristics and limits of a method and identification of the effects which may change these features and to what extent. This article discusses the current and potential uses of the drug mycophenolic acid as well as the plans and the subjects related to designing UV and HPLC method for development and validation. \u0000Keywords: Mycophenolic acid, Immunosuppressant, HPLC, UV, Validation","PeriodicalId":14229,"journal":{"name":"International Journal of Pharmaceutical and Biological Science Archive","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78991494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FORMULATION AND EVALUATION OF COLON TARGETED PELLETS OF BUMADIZONE CALCIUM","authors":"Shah Akashkumar Nareshkumar, Anil G. Raval","doi":"10.32553/IJPBA.V7I3.125","DOIUrl":"https://doi.org/10.32553/IJPBA.V7I3.125","url":null,"abstract":"Aim: The aim of this study was to Formulation and Evaluation of colon targeted pellets of Bumadizone Calcium \u0000Objective: Bumadizone Calcium is an acetic acid derivative, having irritation in stomach. Bumadizone Calcium has short half-life (4hrs) and undergoes first pass metabolism. It is pH-dependent. This research work was carried out to improve the bioavailability, patient compliance on oral colon targeted drug delivery. Bumadizone Calcium sustained release enteric coated pellets were prepared, which minimize the release of drug in stomach for treatment of IBD formulated by Extrusion Spheronization process. \u0000Experimental work done: Enteric coated pellets prepared by Extrusion Spheronization technique. Eudragit S100, HPMC, PVP K30, and Ethyl Cellulose were used as rate controlling polymers. In this study, a pH dependent colon targeted enteric coated pellets was established using 32 full factorial design by giving enteric coating with Eudragit S100. Different Concentration of Eudragit S100 as an enteric coating material (4%, 5%, & %6) and PVP K30 as a Binder (0.5%, 1% & 1.5%) are taken for the measurements of % Drug Release that are performed by using USP dissolution 1 (Basket type) at 50 rpm. The test is performed with gastric fluid (pH 1.2) at 37±0.5 for first 2 hours & then in phosphate buffer 6.8 for 4 hrs & finally in phosphate buffer pH 7.4 for 6 hrs. The prepared formulations were evaluated for drug-excipient compatibility study, flow property, drug content, and coating process efficiency. \u0000Results and Discussion: Optimized batch shown that less than 0.50% of the drug released at the end of 2 hrs in pH 1.2, less than 20% of drug released after end of 4 hrs in pH 6.8 and more than 85% at the end of 12 hrs in pH 7.4. \u0000Conclusion: Bumadizone Calcium Enteric Coated pellets can be successfully formulated by addition of PVP K-30 as a binder and Eudragit S100 as Coating polymer. It was also concluded that prepared formulation minimizes drug release in stomach and avoid side effect of the drug. \u0000Keywords: Bumadizone calcium, Eudragit S100, Enteric coating, extrusion spheronization technique, 32 full factorial designs.","PeriodicalId":14229,"journal":{"name":"International Journal of Pharmaceutical and Biological Science Archive","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77981073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A REVIEW ON COMPARITIVE STUDY ON SAFETY AND EFFECTIVENESS OF IV FERRIC CARBOXY MALTOSE VERSUS IRON SUCROSE IN PATIENTS WITH IRON DEFICIENCY ANAEMIA OF CKD","authors":"L. S, R. Manju, M. George, L. Joseph","doi":"10.32553/ijpba.v7i2.123","DOIUrl":"https://doi.org/10.32553/ijpba.v7i2.123","url":null,"abstract":"Deficiency of iron is one of the most common nutritional disorders in the society. Iron deficiency anemia is described as decreased production in red blood cells (RBCs) due to low body iron stores.Anemia commonly occurs in people with chronic kidney disease and it might begin to develop in the early stages and tends to worsen as disease progresses. Iron supplementation is mandatory in the majority of patients with renal disease, particularly in those receiving ESA therapy. Treatment with intravenous iron in some clinical situations could present some advantages over oral iron, such as faster and higher increases of hemoglobin (Hb) levels and body iron stores. Some modern formulations of intravenous iron have emerged as a safe and effective alternative for iron deficiency anaemia management. E.g.: iron sucrose. Ferric carboxy maltose is a parenteral iron dextran-free product and the first of the new agents approved for rapid and high-dose replenishment of depleted iron stores. \u0000Keywords:  Iron deficiency anaemia, chronic kidney disease, hemoglobin, iron sucrose, ferric carboxy maltose","PeriodicalId":14229,"journal":{"name":"International Journal of Pharmaceutical and Biological Science Archive","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87048012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A REVIEW ON A COMPARATIVE STUDY ON EFFECTIVENESS AND SAFETY OF NOVEL ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION","authors":"P. K, M. George, L. Joseph","doi":"10.32553/ijpba.v7i2.122","DOIUrl":"https://doi.org/10.32553/ijpba.v7i2.122","url":null,"abstract":"Atrial fibrillation (AF) is characterized as an extremely rapid and disorganized atrial activation. These irregular heartbeats will cause blood to collect within the heart and potentially form a clot, which can travel to a person’s brain and cause a stroke. AF increases stroke risk by 3 to 5 fold. Vitamin K antagonists (VKAs) are highly effective for the prevention of stroke, mainly of ischemic origin, in patients with AF. For this reason, VKAs are currently recommended in all AF patients at moderate to high risk for stroke or systemic embolism (SSE). VKAs have significant limitations, particularly their unpredictable anticoagulant response and numerous food and drug interactions, mandating regular laboratory monitoring. These limitations make treatment with VKAs problematic for many patients; as a result, only about half of all potentially eligible AF patients are treated with VKAs. Over the last several years, novel oral anticoagulant drugs (NOACs), including direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (apixaban & rivaroxaban), have been developed. New orally administered anticoagulant drugs have emerged as potential alternatives to VKAs for the prevention of ischaemic stroke or systemic embolism in patients with chronic atrial fibrillation. Novel oral anticoagulants (NOACs), due to their a lot of predictable therapeutic result and more favorable haemorrhagic risk profile, represent a particularly attractive therapeutic option in AF patients. \u0000Keywords:  Novel oral anticoagulants (NOACs), Vitamin K antagonist (VKAs), Atrial fibrillation, Apixaban, Dabigatran, Rivaroxaban.","PeriodicalId":14229,"journal":{"name":"International Journal of Pharmaceutical and Biological Science Archive","volume":"129 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86001374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A REVIEW ON THE EFFECT OF FEBUXOSTAT IN CHRONIC KIDNEY PATIENTS, IT’S SIGNIFICANCE IN eGFR, URIC ACID AND ALBUMINURIA.","authors":"Jinsu Deena Jose, M. George, L. Joseph","doi":"10.32553/ijpba.v7i2.121","DOIUrl":"https://doi.org/10.32553/ijpba.v7i2.121","url":null,"abstract":"Chronic kidney disease is defined as the abnormality of the kidney structure or function for≥ 3 months and is associated with an irreversible reduction of the excretory and the endocrine functions of the kidney. An important risk factor for the development and progression of CKD is hyperuricemia. Hyperuricemia can occur as a result of the increased production or the reduced secretion of uric acid. Increased uric acid level is significantly associated with a greater decline in renal function and there is a higher risk of progression into kidney failure. Febuxostat is a nonpurine xanthine oxidase inhibitor for the treatment of hyperuricemia in patients with chronic kidney disease. It reduces serum uric acid concentrations by blocking the transformation of hypoxanthine to xanthine and xanthine to uric acid. Febuxostat is mainly metabolized in the liver and excreted through both urine and feces. Renal adjustment is also not required in CKD patients with mild to moderately reduced eGFR as it is metabolized mainly by glucuronidation and oxidation in the liver and well excreted by both urinary and fecal routes. Recent studies show that, in addition to lowering the uric acid level, febuxostat preserves the eGFR. \u0000Keywords:  Chronic kidney disease, hyperuricemia, febuxostat, eGFR","PeriodicalId":14229,"journal":{"name":"International Journal of Pharmaceutical and Biological Science Archive","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74705111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A REVIEW ON COMPARATIVE STUDY ON THE SAFETY AND EFFECTIVENESS OF SACUBITRIL-VALSARTAN COMBINATION WITH ACE/ARB THERAPY IN CARDIAC PATIENTS","authors":"B. Suresh, M. George, L. Joseph","doi":"10.32553/ijpba.v7i2.120","DOIUrl":"https://doi.org/10.32553/ijpba.v7i2.120","url":null,"abstract":"Cardiovascular (CV) disease is a major cause of morbidity and mortality in the developing and the developed world, and represents a major barrier to sustainable human development. Ischemic heart disease, cerebrovascular disease, cardiomyopathy and heart failure (HF), and hypertension among others represent major forms of CV disease. Heart failure (HF) is among the key contributors to the CV-related health care burden, a uninterrupted concern despite the utilization of clinically tried guideline-directed therapies. The most common cause for HF is reduced left cavum heart muscle perform. ARBs produce equivalent mortality benefits with fewer adverse effects than ACE inhibitors. Angiotensin converting enzyme (ACEI) reduces the combined risk of death or hospitalization, slow progression of HF, and reduced rate of reinfarction. Sacubitril/valsartan could be a first-in-class twin action molecule of the neprilysin (NEP) substance sacubitril (AHU-377) and therefore the angiotensin II (Ang II) sort one (AT1) receptor blocker (ARB) valsartan. The beneficial antihypertensive and HF effects of sacubitril/valsartan are mediated through the inhibition of NEP in catabolizing the natriuretic peptides (NPs) and the blockade of Ang II, AT1 receptor with valsartan. These actions of sacubitril/ valsartan end in general dilation and inflated symptoms and symptoms, resulting in decrease in peripheral tube resistance and plasma volume contraction, all necessary actions for the lowering of BP and improving HF symptoms. \u0000Keywords:  cardiovascular disease, left ventricular ejection fraction, angiotensin II receptor blocker, angiotensin converting enzyme, sacubitril/valsartan.","PeriodicalId":14229,"journal":{"name":"International Journal of Pharmaceutical and Biological Science Archive","volume":"718 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76912291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“FORMULATION AND EVALUATION OF BUCCAL FILMS OF SAXAGLIPTIN”","authors":"V. Pandit, V. Patel","doi":"10.32553/ijpba.v7i2.119","DOIUrl":"https://doi.org/10.32553/ijpba.v7i2.119","url":null,"abstract":"Objective: Saxagliptin is an orally anti-diabetic drug. It has an oral bioavailability of 50% due to first pass hepatic metabolism. To achieve sustained action of drug, reduce dosing frequency, bypass the hepatic first pass effect and improve bioavailability, buccal films formulation was planned. \u0000Methods: Compatibility of the drug with the excipients was studied with the help of FTIR. 23 factorial design was planned using concentration of Sodium alginate, concentration of Chitosan and PEG 400. Solvent casting method was used for the fabrication of films. Weight, thickness, surface pH, mucoadhesive strength, in vitro residence time, % swelling and % drug release were evaluated for the prepared film formulations. \u0000Results: All the films were found have surface pH close to neutral pH and were found to have content uniformity. Mucoadhesive strength was found to increase with increase in concentration of Chitosan. Drug release is more controlled by the high swelling film formers than sodium alginate. Among the film formers, though swelling is more, % drug release is also more from sodium alginate and Chitosan films because of its ionic nature and more solubility. \u0000Conclusion: Because of high mucoadhesive strength and more % drug release, combination of Sodium alginate with Chitosan film formulations was selected. \u0000 Key Words: Saxagliptin, Buccal films","PeriodicalId":14229,"journal":{"name":"International Journal of Pharmaceutical and Biological Science Archive","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81413676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FORMULATION AND EVALUATION OF ORODISPERSIBLE TABLETS OF PALIPERIDONE","authors":"Kaushikbhai Ghanshyambhai Gajera, Anil G. Raval","doi":"10.32553/ijpba.v7i2.116","DOIUrl":"https://doi.org/10.32553/ijpba.v7i2.116","url":null,"abstract":"Optimized orally disintegrating tablets (ODTs) containing Paliperidone were prepared by direct compression method. Two factors, three levels (32) full factorial design was used to optimize the effect of superdisintegrant (crospovidone; X1) and; Binder (PVP K30S; X2) on tablet properties. The prepared ODTs were characterized for their drug content, hardness, friability and wetting time. The optimized ODT formulation (P4) was evaluated in term of in vitro disintegration and dissolution. The manufactured ODTs were complying with the pharmacopeia guidelines regarding hardness, friability, weight variation and content. PVP K30 had a very slightly enhancing effect on tablets disintegration. However, the effects of both Crospovidone (X1) and PVP K30 (X2) on ODTs drug release (Y1) were significant (p < 0.05). Moreover, X1 exhibited significant effect on the disintegration time. Furthermore, the optimized ODTs formula showed 1 month stability, and in vitro disintegration time of this formula was about 33 s. \u0000Key Words: Paliperidone, orally disintegrating tablets","PeriodicalId":14229,"journal":{"name":"International Journal of Pharmaceutical and Biological Science Archive","volume":"98 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73842431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FORMULATION AND EVALUATION OF SUBLINGUAL FILMS OF APIXABAN","authors":"Arjun Joshi, Anil G. Raval","doi":"10.32553/ijpba.v7i2.117","DOIUrl":"https://doi.org/10.32553/ijpba.v7i2.117","url":null,"abstract":"The concept of sublingual film dosage form has become popular as new delivery system. This system will provide maximum therapeutic efficacy, increased bioavailability and maximum stability by reducing the frequency of dosage. It will also avoid first pass metabolism of the drugs. This system provides more rapid drug absorption from the pre gastric area which may provide quick onset of action. The present research aimed to prepare sublingual films of apixaban reduces the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The film was prepared using solvent casting method and optimized employing 32 factorial design considering two independent variables film forming polymer (HPMC E5) and PEG 400. Disintegration time, drug release and folding endurance were taken as dependent variables. The prepared optimized formulation showed minimum disintegration time (35 s), highest dissolution rate (99 %) and satisfactory physicochemical properties. It is evident from the above results that the developed formulation can be an innovative dosage form to improve the drug delivery, onset of action as well as improve patient compliance. \u0000Key Words: Apixaban, Sublingual films, HPMC","PeriodicalId":14229,"journal":{"name":"International Journal of Pharmaceutical and Biological Science Archive","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88627660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FORMULATION AND EVALUATION OF ORALLY DISINTEGRATING TABLETS OF MIRABEGRON","authors":"Kajal A. Prajapati, D. Patel, Anil G. Raval","doi":"10.32553/ijpba.v7i2.118","DOIUrl":"https://doi.org/10.32553/ijpba.v7i2.118","url":null,"abstract":"Mirabegron Orally Disintegrating Tablets were prepared using a direct compression approach with a novel approach of combining effervescence agents and super disintegrants to achieve a rapid disintegration. A screening study was performed using Crospovidone XL 10, Croscarmellose Sodium and Sodium Starch Glycolate at two levels to least Disintegration Time, which was achieved by Croscarmellose Sodium. The prepared tablets were evaluated for Weight variation, Thickness, Hardness, Disintegration time, Dissolution, and Water uptake study. A full factorial statistical optimization was carried out on the best optimized formulation to establish the design space for selected factors i.e., Level of Effervescence agents and Croscarmellose Sodium against Response Disintegration Time and Dissolution. A significant effect of both factors was found on DT as well as Dissolution rate, which justifies the use and rationale of the excipients. \u0000Key words: Mirabegron, ODT, Direct Compression, Effervescence agents, Super disintegrants","PeriodicalId":14229,"journal":{"name":"International Journal of Pharmaceutical and Biological Science Archive","volume":"50 8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76576030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}